In preclinical studies, dovitinib showed the ability to inhibit FGFR1‐ and FGFR2‐amplified, but not FGFR‐normal breast cancer cell lines in vitro and inhibit tumour growth in FGFR1‐amplified breast cancer in vivo.150. The gene discussed is FGFR2; the disease is neoplasm.